Maternal Serum Vascular Endothelial Growth Factor during Early Pregnancy

1997 ◽  
Vol 92 (6) ◽  
pp. 567-571 ◽  
Author(s):  
Phylip Evans ◽  
Timothy Wheeler ◽  
Frederick Anthony ◽  
Clive Osmond
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Pregnant Women ◽  
Serum Levels ◽  
Maternal Serum ◽  
Interquartile Range ◽  
Vascular Endothelial ◽  
Serum Concentrations ◽  
Serum Progesterone ◽  
Endothelial Growth Factor

1. The objectives of the study were: (i) to investigate the serum concentrations of vascular endothelial growth factor (VEGF) in pregnant and non-pregnant women; and (ii) to study the relationship between the levels of maternal serum VEGF and the serum concentrations of human chorionic gonadotrophin (hCG) and progesterone during the first trimester. 2. Total immunoreactive VEGF was measured by competitive RIA using recombinant human VEGF165 and a polyclonal antiserum. Serum VEGF was measured in 60 non-pregnant women of child-bearing age. These data were compared with serum VEGF measured in 363 women between 41 and 91 days of gestation. 3. The median serum VEGF concentration was 1.10 μg/l (interquartile range 0.91–1.30) in the nonpregnant women and 2.13 μg/l (interquartile range 1.62–2.77) in the pregnant women. Serum levels of VEGF were significantly higher among the pregnant cohort (P < 0.0001). Serum VEGF concentration was positively correlated with gestational age, increasing until ten completed weeks of pregnancy. Serum VEGF was negatively correlated with maternal height and weight, and positively correlated with serum hCG and serum progesterone (P ≤ 0.0001 in all cases). Serum VEGF was lower in the pregnant women who smoked (P = 0.06). 4. Our data show a positive and highly significant correlation between maternal serum levels of VEGF and hormones reflecting placental function (hCG, progesterone). We speculate that VEGF production is increased by progesterone and hCG, and that VEGF has a positive influence on trophoblast development. VEGF may also be involved in the initiation of the maternal cardiovascular adaptation to pregnancy.

scholarly journals The diagnostic Value of Vascular Endothelial Growth Factor in Women with Growth-Restricted Fetuses

Doctor Ru ◽  
2020 ◽  
Vol 19 (8) ◽  
pp. 44-48
Author(s):  
I.F. Fatkullin ◽  
◽  
N.R. Akhmadeev ◽  
E.V. Ulyanina ◽  
L.Kh. Islamova ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Pregnant Women ◽  
Fetal Growth ◽  
Serum Levels ◽  
Diagnostic Value ◽  
Vascular Endothelial ◽  
Group I ◽  
Low Weight ◽  
Endothelial Growth Factor

Study Objective: To assess delivery outcomes in women with slow fetal growth (ICD-10 code P05) and study serum levels of vascular endothelial growth factor (VEGF) and its diagnostic value in patients with growth-restricted fetuses that have constitutional low weight, in order to choose an approach to pregnancy management. Study Design: This was a prospective and retrospective comparative study. Materials and Methods: The medical charts of 782 women who had given birth to low-weight babies in 2013 and 2014 were reviewed retrospectively. The prospective part of the study involved measuring serum levels of VEGF in 150 pregnant women: 50 women with growthrestricted fetuses (Group I), 50 women with low-weight fetuses without hemodynamic disruptions or placental abnormalities (Group II), and 50 women with healthy pregnancies (Group III). Based on the babies’ gestational term at birth, the women in each group were divided into two subgroups: between 22 weeks and 0 days and 31 weeks and 6 days (subgroup 1) and ≥32 weeks and 0 days (subgroup 2). The data obtained were processed using descriptive statistics and compared with data obtained through other fetal assessments. Study Results: The pregnant women with growth-restricted fetuses had higher VEGF levels by a statistically significant margin (p<0.00001) than the women in groups II and III: median levels were 310 (Q1–Q3: 270–508), 33 (Q1–Q3: 31–38), and 36 (Q1–Q3: 32–40) pg/mL, respectively, in subgroups 1 and 174 (Q1–Q3: 100–214), 78 (Q1–Q3: 73–86), and 82 (Q1–Q3: 78–88) pg/mL, respectively, in subgroups 2. VEGF levels ≥100 pg/mL were associated with fetal growth restriction (FGR) (p = 0.0001) and levels ≥200 pg/mL with a high risk of antenatal fetal death (p = 0.026) or early neonatal death (p = 0.03). Conclusion: For women with growth-restricted fetuses, VEGF serum levels ≥200 pg/mL are an additional risk factor for unfavorable perinatal outcomes, which helps to optimize obstetrical management for these patients. Keywords: low-weight fetus, fetal growth retardation, vascular endothelial growth factor.

Serum levels of vascular endothelial growth factor in patients with gastrointestinal cancers and correlation with malnutrition, immunosuppression involving MDSC, and systemic inflammation.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 514-514
Author(s):  
Kenji Gonda ◽  
Masahiko Shibata ◽  
Satoshi Suzuki ◽  
Izumi Nakamura ◽  
Kensuke Kumamoto ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Healthy Volunteers ◽  
Systemic Inflammation ◽  
Lymphocyte Count ◽  
Serum Levels ◽  
Retinol Binding Protein ◽  
Vascular Endothelial ◽  
Serum Concentrations ◽  
Endothelial Growth Factor

514 Background: Vascular endothelial growth factor (VEGF) reportedly plays an important role in the progression of malignant neoplasms, and have been reported to induce myeloid-derived suppressor cells (MDSC) that appears in cancer and inflammation. Methods: Blood samples were collected from 57 patients, including 8 with esophageal cancer, 20 with gastric cancer, 29 with colorectal cancer, and from 18 healthy volunteers. We measured serum concentrations of VEGF and analyzed correlations with nutritional damage, immune suppression and systemic inflammation. As markers of immune function, IL-12 production of PBMC and MDSC (CD 11b+, CD14-, CD33+) were measured. Serum concentrations of albumin and rapid turnover protein were measured as a marker of nutritional status. Results: A significant increase in serum levels was seen in patients with esophageal, gastric, and colorectal cancers compared to healthy volunteers. Levels of VEGF were inversely correlated with serum concentrations of albumin, prealbumin and retinol-binding protein. Serum concentrations of VEGF were inversely correlated with the production of interleukin (IL)-12 and correlated with MDSC. VEGF levels also correlated with neutrophil count and neutrophil/lymphocyte count, and correlated inversely with lymphocyte count. Serum VEGF levels were then divided about a cutoff of 500 pg/ml, with levels of prealbumin and retinol-binding protein significantly decreased in patients with higher VEGF levels. Stimulation index and IL-12 production were significantly decreased in the group with higher VEGF levels, and MDSC counts tended to be higher in this group. Conclusions: These results demonstrated that increased production of VEGF correlated with systemic inflammation, nutritional impairment and inhibition of cell-mediated immunity involving MDSCs. An inactivation of dendritic cells may be occurring by the activation of MDSC. Anti-VEGF therapy may be of importance in treating digestive system cancers.

scholarly journals Serum Levels of Asymmetric Dimethylarginine, Vascular Endothelial Growth Factor, and Nitric Oxide Metabolite Levels in Preeclampsia Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Marjan Noorbakhsh ◽  
Maryam Kianpour ◽  
Mehdi Nematbakhsh
Keyword(s):  
Nitric Oxide ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Pregnant Women ◽  
Asymmetric Dimethylarginine ◽  
Serum Levels ◽  
Hypertensive Disorder ◽  
Vascular Endothelial ◽  
Angiogenic Growth Factors ◽  
Endothelial Growth Factor

Background. Hypertensive disorder generally complicates 5–10 percent of all pregnancies. Angiogenic growth factors may be helpful for the diagnosis and prediction of preeclampsia. Therefore, in this study we attempted to determine the serum levels of asymmetric dimethylarginine (ADMA), vascular endothelial growth factor (VEGF), and nitric oxide (NO) metabolite (nitrite) in preeclampsia patients and compared the levels with those obtained from normal pregnant women. Methods. Ninety pregnant women (19–33 years old) in two groups of preeclampsia and normal were considered during 2012. The levels of ADMA, VEGF, and nitrite were measured in maternal serum samples using ELISA kits. Results. Significant increase of VEGF and nitrite levels was observed in preeclampsia patients when compared with other groups (P<0.05). The serum level of ADMA demonstrated a similar increased trend in preeclampsia patients; however, the increase was not statistically significant (P=0.08). Conclusion. The findings reveal that the elevation of serum levels of VEGF and nitrite and possibly ADMA may be involved in the pathogenesis of preeclampsia.

Predictive value of vascular endothelial growth factor and placenta growth factor for morbidly adherent placenta among women with previous history of cesarean section

2020 ◽  
Author(s):  
Nasrin Asadi ◽  
Mojgan Akbarzadeh-Jahromi ◽  
Azam Faraji ◽  
Shima Bahrami ◽  
Sayeh Gharamani ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Serum Level ◽  
Pregnant Women ◽  
Placenta Accreta ◽  
Maternal Serum ◽  
Vascular Endothelial ◽  
Placenta Growth Factor ◽  
Placenta Accreta Spectrum ◽  
Endothelial Growth Factor

Abstract Background The present study aims to determine the predictive value of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) for placenta accreta and for the comparison of the serum level of VEGF and PLGF in normal pregnant women and women with placenta accreta spectrum (PAS).Methods This prospective case-control study was conducted during the 2 years in two hospital in Shiraz, Iran from 2017 to 2019. The inclusion of the study was 90 singleton pregnant women: 45 of them in gestational ages of 28-34 weeks with pathological confirmation of placenta accreta spectrum and 45 healthy pregnant women. In the PAS group, according to pathology reports on the placenta, we divided all cases to placenta accreta, percreta, and increta. Maternal serum level of VEGF and PLGF were measured before the termination of pregnancy and diagnostic accuracy of each factor was evaluated.Results In PAS group, 75 percent of patients had placenta previa and unlike the control group, there was a significant difference in the gravidity, number of cesarean section, maternal age, and serum level of PLGF (p< /001); while in VEGF, the difference was not statistically significant.Conclusions The results of the present study revealed that the maternal serum level of PLGF could be considered as an accurate predictive test in patients with PAS.

scholarly journals Suppression of Extravillous Trophoblast Vascular Endothelial Growth Factor Expression and Uterine Spiral Artery Invasion by Estrogen during Early Baboon Pregnancy

Endocrinology ◽  
2008 ◽  
Vol 149 (10) ◽  
pp. 5078-5087 ◽  
Author(s):  
Thomas W. Bonagura ◽  
Gerald J. Pepe ◽  
Allen C. Enders ◽  
Eugene D. Albrecht
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Serum Levels ◽  
Maternal Serum ◽  
Extravillous Trophoblast ◽  
Mrna Levels ◽  
Vascular Endothelial ◽  
Spiral Artery ◽  
Vegf Mrna ◽  
Endothelial Growth Factor

We have shown that advancing the increase in maternal serum estrogen levels from the second to the first third of baboon pregnancy suppressed extravillous cytotrophoblast (EVT) spiral artery invasion. Because vascular endothelial growth factor (VEGF) promotes EVT invasion, the present study determined whether EVT VEGF expression is altered by prematurely elevating estrogen in early pregnancy. Placental basal plate was obtained on d 60 of gestation (term is 184 d) from baboons treated daily on d 25–59 with estradiol (0.35 mg/d sc), which increased maternal peripheral serum estradiol levels 3-fold above normal. Overall percentage of uterine arteries (25 to more than 100 μm in diameter) invaded by EVT assessed by image analysis in untreated baboons (29.11 ± 5.78%) was decreased 4.5-fold (P &lt; 0.001) by prematurely elevating estrogen (6.55 ± 1.83%). VEGF mRNA levels in EVT isolated by laser capture microdissection from the anchoring villi of untreated baboons (6.77 ± 2.20) were decreased approximately 5-fold (P &lt; 0.05, ANOVA) by estradiol (1.37 ± 0.29). Uterine vein serum levels of the truncated soluble fms-like receptor, which controls VEGF bioavailability, in untreated baboons (403 ± 37 pg/ml) were increased 3-fold (P &lt; 0.01) by estrogen treatment (1127 ± 197 pg/ml). Thus, placental EVT expression of VEGF mRNA was decreased and serum soluble truncated fms-like receptor levels increased in baboons in which EVT invasion of the uterine spiral arteries was suppressed by advancing the rise in estrogen from the second to the first third of pregnancy. We suggest that VEGF mediates the decline in EVT vessel invasion induced by estrogen in early primate pregnancy.

Sign in / Sign up

Export Citation Format

Share Document